---
type: "Nootropic"
title: "modafinil"
description: "Modafinil is a prescription wakefulness medicine for excessive sleepiness associated with specified sleep disorders. It does not replace sleep; cognitive benefits in healthy people vary by task and baseline condition and do not guarantee superior performance across all domains."
resource: "https://nootropikler.com/nootropics/modafinil"
tags: ["alertness", "Focus", "Executive Functions"]
timestamp: 2026-11-11T00:00:00Z
category: "Energy"
source: "synthetic"
latin: "Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide)"
language: "en"
---

# modafinil

*Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide)*

Modafinil is a prescription wakefulness medicine for excessive sleepiness associated with specified sleep disorders. It does not replace sleep; cognitive benefits in healthy people vary by task and baseline condition and do not guarantee superior performance across all domains.

## Quick profile

| Property | Value |
| --- | --- |
| Onset of Effect | No established timeframe |
| Half life | About 15 hours (multiple doses, US label) |
| Dose used in research | Determined by the prescriber |
| Safety | See detailed safety warnings |
| Level of Evidence | Depends on the indication and outcome measured |

> Correction · 2026-11-11: The half-life measurement context was specified. Contraception intervals now identify their country and source.

> **⚠ Medication Requiring a Prescription:** The US PROVIGIL product information describes modafinil as a controlled prescription medicine. For a specific product in Türkiye, verify authorization, prescribing conditions and approved indications in current TİTCK records and product information. This general explanation does not determine the legal status of nonprescription sales or personal use.

## What is Modafinil?

Modafinil is a prescription wakefulness-promoting drug approved in the United States in 1998. The US PROVIGIL label covers excessive sleepiness associated with narcolepsy, obstructive sleep apnea or shift work disorder in adults. It does not treat the underlying airway obstruction in sleep apnea.

Modafinil is a prescription wakefulness medicine for excessive sleepiness associated with specified sleep disorders. It does not replace sleep; cognitive benefits in healthy people vary by task and baseline condition and do not guarantee superior performance across all domains.

## Mechanism of Effect

The US PROVIGIL label states that the full mechanism promoting wakefulness is unknown. Dopamine-transporter binding and reuptake inhibition have been demonstrated; experimental findings involving other circuits are not established cognitive outcomes in humans.

Most mechanism findings in this section come from cell or animal experiments; they do not establish the same effects or clinical benefits in humans.

## Clinical Evidence

**Battleday and Brem (2015)** published a **systematic review** of 24 studies in healthy, non-sleep-deprived people; it was not a quantitative meta-analysis. Some learning and complex-task measures improved, while simple-task findings were mixed. These results do not establish general or long-term cognitive superiority or a safe self-use protocol in healthy people.

Modafinil carries a risk of misuse. The US PROVIGIL label classifies it as a Schedule IV controlled substance and reports euphoric/stimulant effects in humans. Different pharmacology does not mean protection from dependence or safety of unsupervised use.

## Dose information and research limits

> **Dose information and research limits:** This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

## Safety and Side Effects

Modafinil does not replace sleep and should follow the prescriber’s plan. No validated “two or three days a week” nootropic cycle exists. The PROVIGIL label warns about serious rash/Stevens–Johnson syndrome, angioedema, psychiatric symptoms and cardiovascular events. New rash, chest pain or psychosis/mania symptoms require stopping the medicine and immediate medical assessment.

- headache

- nausea

- insomnia

Modafinil can reduce the effectiveness of steroidal contraception during treatment. The US PROVIGIL label specifies 1 month of precautions after stopping, and the UK MHRA notice specifies 2 months. The MHRA advises against use during pregnancy.


## Frequently Asked Questions

### What does Modafinil do?

Modafinil is a prescription wakefulness medicine for excessive sleepiness associated with specified sleep disorders. It does not replace sleep; cognitive benefits in healthy people vary by task and baseline condition and do not guarantee superior performance across all domains.

### Is Modafinil legal in Türkiye?

Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.

### Is Modafinil addictive?

Modafinil affects the dopamine transporter and has a nonzero misuse/dependence risk. It is a controlled prescription medicine in the US. Follow the prescriber’s treatment plan rather than changing dose or frequency yourself; intermittent use is not a proven method of preventing dependence.

### Can Modafinil and coffee/caffeine be taken together?

Controlled studies have not adequately established the efficacy and safety of these combinations in healthy people. Theoretical complementarity is not proven synergy or a recommendation to combine them.

## Sources

- Battleday RM, Brem AK. (2015). Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review. *European Neuropsychopharmacology*, 25(11), 1865–1881. [PubMed · PMID 26381811](https://pubmed.ncbi.nlm.nih.gov/26381811/)
- Minzenberg MJ, Carter CS. (2008). Modafinil: a review of neurochemical actions and effects on cognition. *Neuropsychopharmacology*, 33(7), 1477–1502. [PubMed · PMID 17712350](https://pubmed.ncbi.nlm.nih.gov/17712350/)
- Müller U, et al. (2013). Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. *Neuropharmacology*, 64(5), 490–495. [PubMed · PMID 22820554](https://pubmed.ncbi.nlm.nih.gov/22820554/)
- Volkow ND, et al. (2009). Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. *JAMA*, 301(11), 1148–1154. [PubMed · PMID 19293415](https://pubmed.ncbi.nlm.nih.gov/19293415/)
- US National Library of Medicine. PROVIGIL (modafinil): Prescribing Information and Medication Guide. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16c26ad-7bc2-d155-3a5d-da83ad6492c8 [US National Library of Medicine · DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16c26ad-7bc2-d155-3a5d-da83ad6492c8)
- Medicines and Healthcare products Regulatory Agency. (2020). Modafinil (Provigil): increased risk of congenital malformations if used during pregnancy. https://www.gov.uk/drug-safety-update/modafinil-provigil-increased-risk-of-congenital-malformations-if-used-during-pregnancy [Medicines and Healthcare products Regulatory Agency](https://www.gov.uk/drug-safety-update/modafinil-provigil-increased-risk-of-congenital-malformations-if-used-during-pregnancy)

## Related nootropics

- [Sulbutiamine](/okf/nootropics/sulbutiamine.md)
- [Phenylpiracetam](/okf/nootropics/phenylpiracetam.md)
- [rhodiola rosea](/okf/nootropics/rhodiola-rosea.md)
